124-09-4

Applied Filters:

Keyword:'124-09-4'

Showing 1-2 of 2 results for "124-09-4" within Papers

Gerald L Kennedy

Drug and chemical toxicology, 28(1), 15-33 (2005-02-22)

Hexamethylendiamine (HMDA; CAS No. 124-09-4; 6055-52-3 for the dihydrochloride salt) is moderately toxic following acute doses/exposures with oral lethal doses in rats ranging from 750 to 1500 mg/kg. HMDA is extremely irritating to the skin and eyes and is not

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Juan W Valle et al.

The Lancet. Oncology, 16(8), 967-978 (2015-07-17)

Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral

Page 1 of 1